Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net income	$ 243.1	$ 340.5	$ 33.3
Noncash items:
Depreciation	31.8	40.8	42.4
Amortization	106.0	82.8	90.2
Allowance for credit losses	4.8	5.6	23.0
Stock-based compensation expense	30.5	28.2	22.6
Gain on sale of property, plant and equipment	(1.9)	(2.2)	0.0
Gain on sale of KaVo treatment unit and instrument business	(8.9)	(11.7)	0.0
Restructuring charges	4.7	10.8	11.1
Impairment charges	6.4	18.4	32.6
Fair value adjustment of acquisition-related inventory	9.5	0.0	0.0
Amortization of right-of-use assets	24.3	28.3	30.5
Amortization of debt discount and issuance costs	4.1	23.3	13.4
Change in deferred income taxes	(29.0)	(59.0)	(91.4)
Change in trade accounts receivable	(71.0)	(43.2)	71.9
Change in inventories	(39.9)	(66.0)	11.9
Change in trade accounts payable	44.5	(20.3)	21.6
Change in prepaid expenses and other assets	(11.7)	(11.5)	(2.5)
Change in accrued expenses and other liabilities	(133.0)	34.3	10.0
Change in operating lease liabilities	(31.6)	(37.5)	(36.7)
Net cash provided by operating activities	182.7	361.6	283.9
Cash flows from investing activities:
Acquisitions, net of cash acquired	(696.2)	(2.1)	(40.7)
Payments for additions to property, plant and equipment	(75.7)	(54.7)	(47.7)
Proceeds from sales of property, plant and equipment	3.3	11.6	5.3
Proceeds from sale of KaVo treatment unit and instrument business, net	73.9	312.5	0.0
Proceeds from the settlement of derivative financial instruments	56.0	11.4	14.0
All other investing activities, net	(18.6)	(16.0)	0.0
Net cash (used in) provided by investing activities	(657.3)	262.7	(69.1)
Cash flows from financing activities:
Proceeds from revolving line of credit	124.0	0.0	249.8
Repayment of revolving line of credit	(124.0)	0.0	(250.0)
Proceeds from borrowing	0.3	0.0	0.0
Repayment of borrowing	(0.5)	(475.7)	0.0
Proceeds from issuance of convertible senior notes	0.0	0.0	517.5
Payment of debt issuance and other deferred financing costs	0.0	(2.3)	(17.2)
Purchase of capped calls related to issuance of convertible senior notes	0.0	0.0	(20.7)
Proceeds from stock option exercises	21.8	19.5	13.8
Tax withholding payment related to net settlement of equity awards	(9.1)	(7.2)	(5.0)
All other financing activities	0.0	0.1	4.3
Net cash provided by (used in) financing activities	12.5	(465.6)	492.5
Effect of exchange rate changes on cash and cash equivalents	(4.6)	26.0	(29.6)
Net change in cash and cash equivalents	(466.7)	184.7	677.7
Beginning balance of cash and cash equivalents	1,073.6	888.9	211.2
Ending balance of cash and cash equivalents	606.9	1,073.6	888.9
Supplemental data:
Cash paid for interest	38.4	35.7	56.7
Cash paid for taxes	119.2	84.0	28.6
ROU assets obtained in exchange for operating lease obligations	$ 36.0	$ 24.7	$ 28.1